Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose.
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded


This Document Has Been Replaced By: Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)

Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose.

  • March 5, 2004

  • Source: MMWR. Morbidity and mortality weekly report. 2004; 53(8):177-8.
Filetype[PDF-449.72 KB]


  • English
    • Details You May Also Like

    Details:

    • Alternative Title:
      MMWR. Morbidity and mortality weekly report
    • Description:
      On February 13, 2004, CDC recommended that health-care providers temporarily suspend routine use of the fourth dose of 7-valent pneumococcal conjugate vaccine (PCV7) when vaccinating healthy children. This action was taken to conserve vaccine and minimize the likelihood of shortages until Wyeth Vaccines, the only U.S. supplier of PCV7 (marketed as Prevnar), restores sufficient production capacity to meet the national need. Since that recommendation, PCV7 production has been much less than expected because of continuing problems with the PCV7 vial-filling production line. Shipments have been delayed, resulting in spot shortages that might continue beyond summer 2004 and become widespread. Effective immediately, to further conserve vaccine, CDC recommends that all health-care providers temporarily suspend routine administration of both the third and fourth doses to healthy children.
    • Subject:
    • Source:
      MMWR. Morbidity and mortality weekly report. 2004; 53(8):177-8.
    • Pubmed ID:
      15001880
    • Document Type:
      Journal Article
    • Collection(s):
      Guidelines and Recommendations
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov